CPI
CTMX icon

Canaan Partners IX’s CytomX Therapeutics CTMX Stock Holding History

Canaan Partners IX’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		$66.6M Hold
4,244,381
– – 100% 1
2016
Q2 		$43.4M Sell
4,244,381
-640,374
-13% -$7.3M 100% 1
2016
Q1 		$63M Hold
4,884,755
– – 100% 1
2015
Q4 		$102M Buy
+4,884,755
New +$77.3M 100% 1

Other funds holding CTMX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
Tekla Capital Management Boston, Massachusetts $2.56B AUM 18.15% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
VMI
VHCP Management II New York $379M AUM 421.62% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Canaan Partners IX's CTMX Position: Q3 2016 in Review

Canaan Partners IX held its CytomX Therapeutics (CTMX) position steady in Q3 2016 at 4,244,381 shares worth $66.6M. The position accounts for 100% of the portfolio, ranked #1.

Canaan Partners IX first reported a position in CTMX in Q4 2015 and has held it in 4 quarters since. The position peaked at $102M in Q4 2015. 62 funds tracked by Wall St. Rank hold CTMX as of Q3 2016.

  • Canaan Partners IX held 4,244,381 shares of CytomX Therapeutics worth $66.6M as of Q3 2016.
  • Canaan Partners IX left its CytomX Therapeutics share count unchanged in Q3 2016.
  • CytomX Therapeutics made up 100% of Canaan Partners IX's portfolio in Q3 2016, its #1 holding.
  • Canaan Partners IX first reported a position in CytomX Therapeutics in Q4 2015 and has held it in 4 quarters since.
  • Canaan Partners IX's CytomX Therapeutics position peaked at $102M in Q4 2015.
  • 62 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q3 2016.

Based on Canaan Partners IX's 13F filing for Q3 2016, filed 7 Oct 2016.